Clinical Trial Update: A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of the androgen receptor antagonist apalutamide in Chinese participants with metastatic castration-resistant prostate cancer; the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING